Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2023-12-29 Regulatory Filings
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
VERAXA Biotech AG übernimmt Synimmune GmbH zur Erweiterung des Krebsportfolios
Regulatory Filings Classification · 1% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and its subject is 'Fusionen & Übernahmen/Firmenübernahme' (Mergers & Acquisitions/Company Takeover). The content details the acquisition of Synimmune GmbH by VERAXA Biotech AG, including financial terms (up to 32 million EUR). This clearly describes a significant corporate transaction related to M&A activity. Therefore, the appropriate classification is 'Merger Proposals or Takeover Bids' (TAR). Although it is an announcement, the core content is the M&A event itself, not just the announcement of a report, making TAR more specific than RPA or RNS.
2023-12-29 German
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases
Report Publication Announcement Classification · 1% confidence The document is a news release dated December 22, 2023, announcing a research update and a significant milestone (completion of toxicity studies for a PET tracer). It contains company commentary, details about a scientific breakthrough, and a financial calendar listing future reports (Annual Report, Half-Year Report). This format—a brief announcement of operational or research progress, often released via a news wire service (indicated by the EQS News Service footer)—is characteristic of a general regulatory announcement or news update that doesn't fit the specific financial report categories (like 10-K, ER, or IR). Since it is a specific operational/research update and not a standard financial filing, and it is not a proxy statement (DEF 14A) or a director's dealing report (DIRS), the most appropriate general category for non-standard regulatory news is 'Regulatory Filings' (RNS), as it serves as a broad announcement mechanism.
2023-12-22 English
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases
Regulatory Filings Classification · 1% confidence The document is a press release announcing a significant research update regarding a PET tracer (DAZAmed) development milestone (completion of toxicity studies). It contains key operational news, management commentary, and a financial calendar. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), an Earnings Release (ER) focusing only on numbers, or a transcript (CT). Since it is a general announcement of operational progress and news that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a news release disseminated to the market via a service (EQS News Service). The document length is moderate, but its primary function is disseminating timely, non-financial-statement-specific news.
2023-12-22 English
Xlife Sciences AG erreicht bedeutenden Meilenstein in der Entwicklung von Radiodiagnostika für Lebererkrankungen
Regulatory Filings Classification · 1% confidence The document is a press release dated 22.12.2023, announcing a research update/study milestone regarding the DAZAmed PET-tracer development by Xlife Sciences AG. It details scientific progress, quotes the CEO, and includes a financial calendar listing future reports (Annual Report, General Meeting, Half-Year Report). This type of announcement, focusing on operational or research progress rather than formal financial results (ER) or mandatory regulatory filings (10-K, AR), is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a slide deck. Given the format is a news release announcing a specific operational achievement and it doesn't fit the definitions for ER, IR, or specific corporate actions, RNS (Regulatory Filings / General Regulatory Announcements) is the most appropriate fallback category for this type of corporate news release, especially since it is distributed via an EQS News Service.
2023-12-22 German
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
M&A Activity Classification · 1% confidence The document is a press release dated December 20, 2023, announcing an exclusive collaboration and Letter of Intent (LOI) between Xlife Sciences AG and Quant Biomarkers AG regarding the licensing of innovative biomarkers for kidney diseases. The content focuses on a strategic partnership and future licensing negotiations, not the release of periodic financial results (ER/IR), a full annual report (10-K), or a formal shareholder vote result (DVA). Since it announces a significant business development, partnership, and potential future licensing deal, it fits best under the general category of corporate news or regulatory filings that don't fit a more specific financial report type. Given the options, and since it is a news announcement about a strategic business development (partnership/licensing), it is closest to a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the collaboration involved immediate funding, but the primary focus is the partnership itself. As it is a standard corporate news release detailing a business agreement, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback category.
2023-12-20 English
Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
Regulatory Filings Classification · 1% confidence The document is a press release announcing an exclusive collaboration and Letter of Intent between Xlife Sciences AG and Quant Biomarkers AG regarding the development of kidney disease biomarkers. It contains market data, quotes from CEOs, and a financial calendar. This type of announcement, detailing a significant business development (partnership/licensing agreement) that is not a standard regulatory filing (like 10-K, ER, or IR), typically falls under general corporate news or regulatory announcements. Since it is a formal announcement of a strategic business development and partnership, and it is not explicitly a Director's Dealing (DIRS), Capital Change (CAP), or M&A (TAR), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered by more specific codes. The document structure resembles a standard media release, not a detailed financial report or presentation.
2023-12-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.